ArticleIntestinal Failure (New York, N.Y.)
Incidence, predictors and outcome of neonatal-onset intestinal failure.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal-onset Intestinal Failure (IF) and Short Bowel Syndrome (SBS) are associated with significant morbidity. We aimed to estimate incidence, identify predictors and determine outcomes of neonatal IF and SBS. Materials and methods: Retrospective review of children admitted to Queensland Children's Hospital between April, 2018 to March, 2022 who received parenteral nutrition (PN) in the neonatal period. IF was defined as those who required PN> 60 days from a gastrointestinal cause. Population-based estimate of incidence was calculated using census data from the national bureau of statistics. Results: 49 neonatal patients received PN, of which 21 had IF, including 16 with SBS. The population-based incidence of IF and SBS-IF were 13.7(95 % CI 10.0-17.1) and 10.51(95 % CI 5.04-15.59) per 100,000 live-births respectively. Those with IF had lower birth weight [1985(IQR 1321)g vs.3140(IQR778)g, p = 0.001], lower gestational age [34weeks(IQR7.5)vs.38weeks(IQR3),p = 0.001], shorter residual small bowel [45 cm(IQR44)vs.245 cm(IQR50),p = 0.001], more likely to have an enterostomy [17/21vs.10/28,p = 0.003] and no colon [10/21vs.3/28,p = 0.0001] compared to those without IF. On multivariate analysis, residual small bowel length [OR 0.73(95 %CI 0.57-0.93),p = 0.008] and absent colon [OR 0.84(95 %CI 0.69 - 0.92),p = 0.001] were independent predictors of IF. At follow-up, 71 % (15/21) of patients with IF, including 81 % (13/16) with SBS attained enteral autonomy with no mortality. Children who attained enteral autonomy had significantly longer residual bowel [47.5(IQR 33)cm. vs. 26 cm.,p = 0.04] as compared to those who remained on PN. Conclusion: The population-based incidence of IF and SBS-IF in Queensland, Australia was 13.7 and 10.51 per 100,000 live-births respectively. Most children with neonatal IF achieve enteral autonomy with residual small bowel length predictive of it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.